Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Journal article published in 2017 by Edward J. Gane, Stephen Pianko, Stuart K. Roberts, Alexander J. Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R. Foster, Kosh Agarwal , Alex L. Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler and other authors. Edward J. Gane, Stephen Pianko, Stuart K. Roberts, Alexander J. Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R. Foster, Kosh Agarwal , Alex L. Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler, Jerry J. Li, Anjana Grandhi, Hong Liu, Feng-Hsiu Su, Shuyan Wan, Zhen Zeng, Huei-Ling Chen, Frank J. Dutko, Bach-Yen T. Nguyen, Janice Wahl, Michael N. Robertson, Eliav Barr, Wendy W. Yeh, Rebeca M. Plank, Joan R. Butterton, Rafael Esteban

Show less

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving forbidden

Policy details

Data provided by